New malaria vaccine trial aims to stop recurrent fever

NCT ID NCT07373301

Not yet recruiting ⭐️ VACCINE ⭐️ Sponsor: Malaria Vaccine and Drug Development Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental vaccine called PvCS/Montanide ISA-51 to see if it can protect against P. vivax malaria, a major cause of recurrent fever and anemia. 72 healthy adults in Colombia will receive either the vaccine or a placebo, then be exposed to infected mosquitoes under medical supervision. Researchers will monitor who gets infected and track side effects to determine if the vaccine is safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PvCS/Montanide ISA-51 vaccine (a synthetic peptide from the malaria parasite combined with an immune-boosting adjuvant)
What this could lead to: If successful, this could lead to the first licensed vaccine against P. vivax malaria, preventing recurrent fever and illness in tropical regions.
What could go wrong: This is a Phase 2 trial with only 72 participants, so results may not apply to larger populations. The vaccine may not provide strong or lasting protection, and side effects like injection-site reactions are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALARIA PREVENTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malaria Plasmodium vivax malaria prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALARIA PREVENTION PLASMODIUM VIVAX INFECTION PLASMODIUM VIVAX MALARIA

Contacts and locations

Locations

Malaria Vaccine and Drug Development Center (MVDC)

Cali, Valle del Cauca Department, 61000, Colombia

More trials for these conditions

Other studies related to the condition(s) this trial covers.